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Objective: Subtherapeutic international normalized ratios are frequently encountered in clinical practice, and pa-
tients with mechanical heart valves with inadequate anticoagulation may be exposed to an increased risk of throm-
boembolic events. There are no data on thromboembolic event risk for these patients.
Methods: We assessed the current practice patterns in the management of patients with mechanical heart valves
with subtherapeutic international normalized ratios and assessed the risk of thromboembolic complications in this
setting. The charts of patients with mechanical heart valves followed up in two anticoagulation clinics were re-
viewed. Patients with a history of stable, therapeutic anticoagulation but with a subtherapeutic international nor-
malized ratio were included. Patients who underwent invasive procedures requiring temporary suspension of
antithrombotic therapy were excluded. Data on use and dose of low–molecular weight heparin bridging therapy
were collected.
Results: The incidence of objectively confirmed thromboembolic events within 90 days after obtaining the index
international normalized ratio was assessed. Two hundred ninety-four patients with mechanical heart valves were
included (mean age 63.3 years, 47.3%male). Low–molecular weight heparin was prescribed in 14 cases (4.8%).
At 90 days, 1 patient had a thromboembolic complication (0.3%, 95% confidence interval 0%–1.9%).
Conclusion: Patients with previously stable, therapeutic anticoagulation with a subtherapeutic international nor-
malized ratio have a low risk of thromboembolic events. Withholding low–molecular weight heparin bridging
therapy is a reasonable therapeutic option in these cases.Patients with mechanical prosthetic heart valves require
long-term antithrombotic prophylaxis with vitamin K antag-
onists (VKAs) to reduce the risk of thromboembolic compli-
cations. In the absence of anticoagulant therapy, the
estimated risk of thromboembolic events for patients with
a prosthetic valve in the aortic position is about 12% per
year rising to 22% per year for patients with a prosthetic
valve in the mitral position.1,2 The American College of
Chest Physicians guidelines recommend long-term antico-
agulant therapy with a target international normalized ratio
(INR) value of 2.5 (range 2.0–3.0) or 3.0 (range 2.5–3.5)
for patients with mechanical prosthetic heart valves,3 de-
pending on the position, the type of valve, and the presence
of additional risk factors. The association of VKAs with as-
pirin is recommended for patients at very high risk (patients
with caged-ball or caged-disk valves or additional risk fac-
tors, such as atrial fibrillation or myocardial infarction) and
in case of systemic embolism despite therapeutic INR
values.3
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clinical practice, and patients with mechanical heart valves
with inadequate anticoagulation may be exposed to an in-
creased risk of thromboembolic events. The current literature,
however, inadequately describes the clinical consequences
associated with exposure to subtherapeutic INR values.
Bridging therapy with low–molecular weight heparin
(LMWH) has been shown to be effective and relatively
safe for patients with mechanical prosthetic heart valves
who require interruption of VKAs for an invasive proce-
dure.4-6 Whether administration of LMWH is also necessary
to prevent thromboembolic complications in patients with
subtherapeutic INR values is currently unknown. Before
a clinical trial assessing the efficacy and safety of LMWH
in this setting is eventually planned, however, better infor-
mation on the actual risk of thromboembolic events for these
patients is required. The purposes of this retrospective co-
hort study were to assess current practice patterns in the
management of patients with mechanical prosthetic heart
valves with subtherapeutic INR values and to asses the
risk of thromboembolic complications in this setting.
MATERIALS AND METHODS
The charts of all patients with mechanical heart valves who were cur-
rently attending or who had attended two anticoagulation clinics in Varese
and Palermo, Italy, were reviewed. At both centers, patients are regularly
followed up for the monitoring of VKA therapy, and information on clinical
events is documented and registered in a computerized database.Cardiovascular Surgery c Volume 137, Number 1 91
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INR ¼ international normalized ratio
LMWH ¼ low–molecular weight heparin
VKA ¼ vitamin K antagonist
Patients were included if they had at least 1 INR value 0.5 to 1 INR units
below the lower limit of the patient-specific target INR range, the 2 INR
values preceding the index INR value were within or greater than the pa-
tient-specific INR target range, and the interval between the 2 INR values
preceding the index INR value was at least 2 weeks. Because risk of throm-
boembolic events is highest in the first 3 months after surgery, only patients
with anticoagulation for more than 3 months were included. Patients who
underwent invasive procedures requiring the temporary suspension of the
antithrombotic therapy were excluded.
The INR value and baseline characteristics, including age, sex, position
(mitral or aortic) and type (caged-ball, caged-disk, tilting-disk, or bileaflet)
of mechanical valve, target therapeutic INR range, concomitant therapy
with aspirin, presence of atrial fibrillation, presence of left atrial dilatation,
presence of heart failure with low ejection fraction, history of stroke or tran-
sient ischemic attack, history of myocardial infarction, were registered
anonymously in a database with a patient number as the only identifier.
The use and dose of LMWH bridging therapy, were also collected. At
each ambulatory follow-up visit, patients were routinely asked about throm-
boembolic complications. Patients absent at a planned ambulatory visit were
contacted by phone; if possible, a new ambulatory visit was planned. Doc-
umentation was requested when a possible thromboembolic complication
was suspected. For each patient included in the study, the occurrence of
thromboembolic events within 90 days after the index INR value was as-
sessed. Only objectively confirmed events were considered.
The primary outcome was the proportion of patients with thromboem-
bolic complications (stroke, transient ischemic attack, peripheral embolism,
symptomatic valve thrombosis) within 90 days after the index INR value
was obtained. The incidences of thromboembolic complications among pa-
tients with and without prophylaxis were also separately analyzed. Source
documents of clinical events were requested and evaluated by 2 investiga-
tors (F.D., A.M.).
Finally, the rate of major bleeding events was also assessed. Patient char-
acteristics were reported as mean  SD and proportion. The 95% confi-
dence intervals were calculated for the end points of the study. The study
was approved by the local ethics committees.
RESULTS
Baseline characteristics are summarized in Table 1.
Agreement between the 2 investigators in reviewing patient
charts was perfect. Three hundred twelve consecutive pa-
tients with mechanical heart valves were identified. Eighteen
did not satisfy inclusion criteria (3 had started oral anticoa-
gulation less than 3 months previously, 15 did not have
any INR value 0.5–1 INR units below the lower limit of
the patient-specific target INR range with the 2 preceding
INR values within or greater than the patient-specific INR
target range), leaving 294 patients eligible for the analysis.
Mean age of included patients was 63.3  11.9 years (range
19–79 years), and 139 were male (47.3%). One hundred
twenty-nine patients had aortic mechanical heart valves
(43.9%), 114 had mitral mechanical heart valves (39.1%),
and 50 had both mitral and aortic mechanical heart valves92 The Journal of Thoracic and Cardiovascular Surg(17.0%). Almost all patients had bileaflet mechanical heart
valves. One third of patients had concomitant atrial fibrilla-
tion, 15.5% had atrial enlargement without fibrillation,
17.4% had a history of myocardial infarction, 13.2% had
a previous stroke or transient ischemic attack, and 14.0%
had low ejection fraction. More than 60% of patients had
at least 1 additional risk factor.
Concomitant antiplatelet therapy with aspirin was used in
20 cases (6.8%). Mean INR value at the time of the presen-
tation was 1.74  0.17, and 84% of patients had a new INR
value determined within 2 weeks. Subsequent INR value
was considered subtherapeutic in 138 patients (46.9%),
and mean duration of subtherapeutic anticoagulation was
16.3 days  9.0. LMWH was prescribed for 14 patients
(4.8%). A prophylactic dose was used in 6 cases and a ther-
apeutic dose in 8 cases.
All patients had a follow-up of at least 90 days. During the
90 days of follow-up, only 1 patient had a thromboembolic
complication (0.3%; 95% confidence interval 0%–1.9%;
1.45 events for 100 patients per year). In a patient with bi-
leaflet mitral and aortic mechanical heart valves and con-
comitant atrial fibrillation, a stroke occurred 8 days after
the index INR value was obtained.
When we consider only patients who did not receive
bridging therapy with LMWH, the incidence of thromboem-
bolic complication was 0.4% (95% confidence interval
0%–2.0%). There were no major bleeding events during
the period of observation.
DISCUSSION
The results of our study suggest that patients with me-
chanical heart valves with previously stable, therapeutic
TABLE 1. Baseline characteristics
Patients (No.) 294
Age (y, mean  SD) 63.3 (11.9%)
Male sex (No.) 139 (47.3%)
Valve position (No.)
Aortic 129 (43.9%)
Mitral 115 (39.1%)
Mitroaortic 50 (17.0%)
Type of valve (No.)
Bileaflet 283 (96.3%)
Caged-disk or tilting-disk 11 (3.7%)
Additional risk factors (%)
Atrial fibrillation 33.3%
Atrial enlargement 15.5%
Coronary heart disease 17.4%
Cerebrovascular disease 13.2%
Heart failure 14.0%
INR value at presentation (mean  SD) 1.74  0.17
Time to next INR measurement (d, mean  SD) 10.3  4.7
Patients with 1 or more subtherapeutic INR values (No.) 138 (46.9%)
Duration of subtherapeutic anticoagulation
(d, mean  SD)
16.3  9.0
INR, International normalized ratio.ery c January 2009
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1.0 INR units below the lower limit of the patient-specific
target INR range) are at low risk for thromboembolic events
in the ensuing 90 days. The validity of our results is strength-
ened by the characteristics of the included population, be-
cause more than 50% of our patients had a mitral or
mitroaortic mechanical heart valve, and more than 60%
had at least one additional risk factor and therefore could
be considered at high risk for thromboembolic complica-
tions. Furthermore, the annual risk of thromboembolic
events in our cohort of patients not receiving LMWH
(1.45 events per 100 patients per year) did not seem to be
higher than the annual risk or thromboembolic events re-
ported in other studies, including those of patients receiving
long-term anticoagulation for mechanical heart valves.3,7
These findings may have clinical importance, since bridg-
ing therapy with LMWH while awaiting the return of the
INR value to the desired range appears to be unnecessary
for these patients. This conclusion is supported on the one
hand by the low observed incidence of thromboembolic
events and on the other hand by the potentially increased
risk of bleeding complications and by the cost associated
with the additional treatment with LMWH.
These results are in agreement with the results of a case–
control study in which the incidence of complications related
to anticoagulation did not differ between a large group of pa-
tients with long-term anticoagulation whose INR values were
at least 0.5 units below the bottom end of the therapeutic INR
range and a group of patients with similar characteristics
whose INR values were within the patient-specific therapeu-
tic range.8 Only a minority of patients included in that study,
however, had prosthetic heart valves, and thus no conclu-
sions for such patients could be drawn in that setting.
Validity of observational retrospective design is a poten-
tial limitation of our study. To avoid misleading results, we
paid meticulous attention to our ascertainment of all throm-
boembolic events by reviewing ambulatory charts of all in-
cluded patients and by contacting patients without completeThe Journal of Thoracic andambulatory charts for follow-up. Absence of a control group
is another potential limitation. The number of thromboem-
bolic events was extremely low in our series of patients,
however, and such events remained uncommon even when
the upper limits of the confidence intervals of our results
were considered. Finally, the number of patients receiving
LMWH was small, and conclusions about this subgroup
are therefore of limited value.
In conclusion, patients with mechanical heart valves and
previously stable therapeutic anticoagulation who have
a subtherapeutic INR value have a low risk of subsequent
thromboembolic events in the ensuing 90 days. Withholding
bridging therapy with LMWH while awaiting return of the
INR value to the desired range appears to a reasonable ther-
apeutic option in these cases. Larger prospective studies are
warranted to confirm our preliminary results.
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